Delayed EGID Diagnosis Can Impair Growth in Children

An Italian study has found that paediatric patients with Eosinophilic Gastrointestinal Diseases EGIDs were prone to be underweight. Symptoms associated with their EGIDs were impeding their weight gain but going undiagnosed. Read more

GI Device Used to Target Early Oesophageal Scarring in Paediatric EoE

Researchers have used a GI device to show that oesophageal distensibility can help clarify the level of scarring in paediatric EoE. This could lead to earlier identification and more targeted intervention. Read more

Dupilumab Maintains Long-Term Efficacy in EoE

The third part of a trial investigating dupilumab in EoE has found the drug maintains its clinical, symptomatic and histologic efficacy and safety profile up to Week 52 in adults and children over 12+. Read more

Update on MESSINA EoE Trial

October 2022 - MESSINA trial of Fasenra in EoE patients demonstrated a significant improvement in histological disease remission but not an improvement in dysphagia symptoms. Read more

Revolo Phase 2 Trial for EoE Completes Enrolment

Enrolment has completed for a Phase 2 trial investigating an immune-resetting molecule in the treatment of EoE. The molecule can reset the immune system from a pro-inflammatory state to a regulated homeostatic state. Read more

New Clinical Severity Index for Management of EoE

The Index, produced by CEGIR researchers, is another step towards global consensus, and is designed to help HCPs monitor EoE severity to make informed decisions about treatment and management. Read more

Positive clinical results for treating EoE in under 12s

July 2022 - A trial investigating dupilimab to treat children under 12 with EoE has achieved positive results. This follows the FDA's approval of dupilimab to treat EoE in adults and children 12 and over earlier this year. Read more

Should patients with IgE allergies be screened for EoE?

A short study has shown a correlation in children with IgE-mediated food allergies reporting symptoms of eosinophilic oesophagitis (EoE), leading researchers to suggest that it may be beneficial to screen IgE-FA patients for EoE. Read more

First UK Patient in MESSINA EoE Trial

The first UK patient has been recruited for the global MESSINA study for benralizumab for EoE. Find study details and see if you're eligible to take part in the Phase 3 trial. Read more

Lirentelimab studies meet histologic endpoints but miss symptomatic endpoints

Allakos has announced that it's ENIGMA (Phase 3) and KRYPTOS (Phase 2/3) studies for lirentelimab in EG & EoD and EoE respectively met histologic endpoints but missed symptomatic endpoints. Read more

FDA rejects application for budesonide treatment

The US FDA has rejected an application for TAK-721 (budesonide oral suspension) for the treatment of EoE in it's present form, and have recommended an additional study to help resolve feedback. Read more

Post-Doctoral Researcher & Research Assistant Opportunities

Two opportunities are available, a Post-Doctoral Researcher and Research Assistant, in the Allergy, Inflammation & Remodelling Research (AIRR) Laboratory of Dr. Joanne Masterson at Maynooth University, Northern Ireland. Read more

Dupilumab Improves EoE Symptoms

Mar 2021 - Phase 3 trial shows Dupilumab to improve health-related quality of life and reduces symptom burden in patients with EoE. Read more

Budesonide Oral Suspension Effective in Paediatric EoE

Mar 2021 - Study finds Budesonide Oral Suspension improves multiple outcomes for children 11-17 with EoE. The drug taken twice-daily improved histologic, endoscopic, and combined histologic and symptomatic outcomes in children with EoE. Read more

Eosinophils and COVID Virtual Seminar

Jan 2021 - The International Eosinophil Society (IES) is holding a virtual seminar on 'Eosinophils and COVID'. Talks will include the involvement of eosinophils in viral infections, Covid-19 and eosinophilic diseases, and vaccine hypersensitivity. Read more

Phase 3 trial for Fasenra in EoE begins

Dec 2020 - AstraZeneca has begun its Phase 3 trial evaluating Fasenra in EoE and other eosinophilic diseases. It has also announced a further Phase 3 trial evaluating the drug for EG and EGE. Read more

Screening data from ENIGMA study reveals under-diagnosis of EG and EGE

Nov 2020 - Growing evidence that Eosinophilic Gastritis and Eosinophilic Gastroenteritis are under-diagnosed. 58% of moderate-severely symptomatic patients without diagnoses who entered the ENIGMA study met histologic criteria for EG/EGE Read more

ENIGMA Lirentelimab lower EGID study published

Nov 2020 - Allakos have published the results of the ENIGMA Phase 2 study of Lirentelimab for EG and EGE patients, showing meaningful and statistically significant benefits. The study appears in the October 2020 edition of the NEJM Read more

Dupilumab EoE Treatment Phase 3 Trial

Oct 2020 - Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Oesophagitis Signs and Symptom Read more

USA National Institute of Health Support Research In Covid-19 and Rare Diseases Including Eosinophilic Diseases

May 2020 - USA National Institute of Health Support Research In Covid-19 and Rare Diseases Including Eosinophilic Diseases- Read the full article here Read more

The future may include diagnostic biomarkers for EG Eosinophilic Gastritis

Feb 2020 - Research into blood and tissue markers for EG Eosinophilic Disease study published by CEGIR. Read more